Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OmniAb, Inc.OABI · Entity 5294 | Chief Legal Officer | April 07, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OmniAb, Inc.
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 399,085 |
Ending reported balance
After 2026-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-07 · Exercise / conversion · Acquired 13,542 · Balance 406,242 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-04-07 · Sale · Disposed 7,157 · Balance 399,085 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 111,042 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 13,542 · Balance 111,042 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,825 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 11,944 · Balance 23,825 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 20,126 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
OmniAb Operations, Inc.
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,587 |
Reported balance
After 2022-11-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-01 · Grant · Acquired 15,409 · Balance 52,587 F1: Includes 9,564 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2: Includes 26,789 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 52,587 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 35,810 |
Reported balance
After 2022-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-01 · Grant · Acquired 35,810 · Balance 35,810 F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-01 · Disposition to issuer · Disposed 35,810 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2025-02-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-01 · Disposition to issuer · Disposed 1,701 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.21 · Expires 2026-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-01 · Disposition to issuer · Disposed 3,627 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.41 · Expires 2027-02-24 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-01 · Disposition to issuer · Disposed 5,966 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $89.36 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-01 · Disposition to issuer · Disposed 8,117 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $66.30 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-01 · Disposition to issuer · Disposed 12,797 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.77 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-01 · Disposition to issuer · Disposed 15,043 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $99.75 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-11-01 · Disposition to issuer · Disposed 6,076 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 9,564 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2: Includes 26,789 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.
F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
F6: The stock option is fully vested and exercisable.
F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2018 Filed Feb 16, 2018 22:40 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 260 | $157.18 | $40,866.80 |
DisclosureSEC source: 0000886163-18-000019 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,059 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:40 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 252 | $157.18 | $39,609.36 |
DisclosureSEC source: 0000886163-18-000019 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,319 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:40 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 524 | $157.18 | $82,362.32 |
DisclosureSEC source: 0000886163-18-000019 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,571 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/10/2015. Read SEC document |
| December 28, 2017 Filed Dec 30, 2017 02:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,175 | $138.66 | $162,925.50 |
DisclosureSEC source: 0000886163-17-000157 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · VP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,095 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 28, 2017 Filed Dec 30, 2017 02:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000157 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · VP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,270 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/10/2015 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the three-year performance period ending December 31, 2017. On December 28, 2017, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| August 09, 2017 Filed Aug 10, 2017 22:40 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 18,625 | $126.96 | $2,364,670.98 |
DisclosureSEC source: 0000886163-17-000098 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · VP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.00 to $128.15, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 243 | $87.13 | $21,171.38 |
DisclosureSEC source: 0000886163-17-000085 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · VP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,048 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 9,643 | $0.00 Strike: $100.38 | $0.00 |
DisclosureSEC source: 0000886163-17-000031 · edgardoc.xml · derivative · entry 3 Berkman Charles S · CIK 0001392266 · VP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,643 Underlying: Common Stock · 9,643 shares Expires 2027-02-24 F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Optioned Shares per month thereafter. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000031 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · VP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,805 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,619 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000031 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · VP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,546 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/10/2015 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the two-year performance period ending December 31, 2016. On February 24, 2017, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.